Search for: "Sanofi S A"
Results 1 - 20
of 933
Sort by Relevance
|
Sort by Date
22 May 2024, 10:00 pm
Sanofi . [read post]
22 May 2024, 10:00 pm
Sanofi . [read post]
22 May 2024, 10:00 pm
Sanofi . [read post]
22 May 2024, 10:00 pm
Sanofi . [read post]
22 May 2024, 10:00 pm
Sanofi . [read post]
22 May 2024, 10:00 pm
Sanofi . [read post]
19 May 2024, 2:55 am
Does the “analogous” art standard still make sense in view of AI's capabilities? [read post]
17 May 2024, 9:37 pm
Sanofi is related because it affirmed a high bar to antibody genus claims based upon the enablement doctrine. [read post]
9 May 2024, 10:55 am
Other pharmaceutical giants, including GSK, Sanofi, and Boehringer Ingelheim, also face numerous lawsuits related to Zantac. [read post]
26 Apr 2024, 12:41 pm
Sanofi, 598 U.S. 594 (2023) and was struck by the Supreme Court’s statement that its 19th Century decision of Wood v. [read post]
23 Apr 2024, 10:28 am
Sanofi. [read post]
14 Apr 2024, 9:05 pm
In Panuwat, the defendant was an employee of Medivation, Inc., a mid-cap oncology firm that was resisting one hostile bidder (Sanofi S.A.) and encouraging another firm (Pfizer) to outbid Sanofi. [read post]
7 Apr 2024, 9:59 pm
Sanofi Pasteur Inc. [read post]
28 Mar 2024, 8:07 pm
Sanofi Pasteur Inc. [read post]
12 Mar 2024, 9:13 pm
Sanofi Pasteur Inc., affirming the Patent Trial and Appeal Board's (PTAB) determination that all claims of U.S. [read post]
7 Mar 2024, 10:00 pm
The Federal Trade Commission’s recent lawsuit to block Sanofi’s acquisition of a pharmaceutical treatment developed by Maze Therapeutics builds on previous enforcement actions and could indicate the agency’s growing willingness to use its so-called “killer acquisition” theory against perceived attempts to eliminate nascent competition, write partners Josh Goodman, Luisa Di Lauro, and Zachary Johns, and associate Molly Maidman. [read post]
7 Mar 2024, 10:00 pm
The Federal Trade Commission’s recent lawsuit to block Sanofi’s acquisition of a pharmaceutical treatment developed by Maze Therapeutics builds on previous enforcement actions and could indicate the agency’s growing willingness to use its so-called “killer acquisition” theory against perceived attempts to eliminate nascent competition, write partners Josh Goodman, Luisa Di Lauro, and Zachary Johns, and associate Molly Maidman. [read post]
7 Mar 2024, 10:00 pm
The Federal Trade Commission’s recent lawsuit to block Sanofi’s acquisition of a pharmaceutical treatment developed by Maze Therapeutics builds on previous enforcement actions and could indicate the agency’s growing willingness to use its so-called “killer acquisition” theory against perceived attempts to eliminate nascent competition, write partners Josh Goodman, Luisa Di Lauro, and Zachary Johns, and associate Molly Maidman. [read post]
7 Mar 2024, 10:00 pm
The Federal Trade Commission’s recent lawsuit to block Sanofi’s acquisition of a pharmaceutical treatment developed by Maze Therapeutics builds on previous enforcement actions and could indicate the agency’s growing willingness to use its so-called “killer acquisition” theory against perceived attempts to eliminate nascent competition, write partners Josh Goodman, Luisa Di Lauro, and Zachary Johns, and associate Molly Maidman. [read post]
7 Mar 2024, 10:00 pm
The Federal Trade Commission’s recent lawsuit to block Sanofi’s acquisition of a pharmaceutical treatment developed by Maze Therapeutics builds on previous enforcement actions and could indicate the agency’s growing willingness to use its so-called “killer acquisition” theory against perceived attempts to eliminate nascent competition, write partners Josh Goodman, Luisa Di Lauro, and Zachary Johns, and associate Molly Maidman. [read post]
